衣康酸在炎症疾病诊治中的研究进展
唐俊鹏 魏娟英 李润琪 邹伟
南华大学附属南华医院神经内科,湖南衡阳 421001
Research progress of itaconic acid in the diagnosis and treatment of inflammatory diseases
TANG Junpeng WEI Juanying LI Runqi ZOU Wei
Department of Neurology, Affiliated Nanhua Hospital, University of South China, Hu’nan Province, Hengyang 421001, China
摘要 衣康酸在人体内主要由巨噬细胞生成,是一种具有抗炎、抗菌等广泛临床应用潜力的物质。衣康酸在炎症、免疫疾病中起着重要作用,衣康酸的抗炎、抗菌机制涉及巨噬细胞的活化、极化、活性氧的生成、代谢重编程、免疫调节、Irg1通路、IκBζ炎症通路等,引起了科学家的广泛关注。研究发现,阻断或增加衣康酸的生成可以促进或抑制疾病的发生与发展,但其在炎症、抗菌的机制尚不完全明确。因此,深入研究衣康酸在疾病中扮演的角色期望为衣康酸在临床疾病中的应用提供参考。
关键词 :
衣康酸 ,
生物标志物 ,
抗菌 ,
炎症 ,
免疫调节
Abstract :Itaconic acid is mainly produced by macrophages in the human body, and it is a substance with extensive clinical application potential such as anti-inflammatory and antibacterial. Itaconic acid plays an important role in inflammation and immune diseases. The anti-inflammatory and antibacterial mechanisms of itaconic acid involve macrophage activation, polarization, generation of reactive oxygen species, metabolic reprogramming, immune regulation, Irg1 pathway, IκBζ inflammation parhrray etc. It has attracted widespread attention from scientists. Studies have found that blocking or increasing the production of itaconic acid can promote or inhibit the occurrence and development of diseases, but its mechanism in inflammation and antibacterial is not completely clear. Therefore, in-depth study of the role of itaconic acid in diseases is expected to provide reference for the application of itaconic acid in clinical drsease.
Key words :
Itaconic acid
Biomarker
Antibacterial
Inflammation
Immunomodulatory
基金资助: 湖南省卫计委重点研究计划项目(A2017020);
湖南省自然科学基金科卫联合项目(2019JJ80057)。
通讯作者:
邹伟(1964.12-),男,主任医师,硕士生导师;研究方向:神经退行性疾病
作者简介 : 唐俊鹏(1995.2-),男,南华大学南华学院2018级神经内科专业在读硕士研究生;研究方向:神经退行性疾病。
[1] Okabe M,Lies D,Kanamasa S,et al. Biotechnological production of itaconic acid and its biosynthesis in Aspergillus terreus [J]. Appl Microbiol Biotechnol,2009,84(4):597-606.
[2] Shin JH,Yang JY,Jeon BY,et al. (1)HNMR-based met-abolomic profiling in mice infected with Mycobacterium tuberculosis [J]. J Proteome Res,2011,10(5):2238-2247.
[3] Kvitvang HF,Andreassen T,Adam T,et al. Highly sensitive GC/MS/MS method for quantitation of amino and nonamino organic acids [J]. Anal Chem,2011,83(7):2705-2711.
[4] Wibom C,Surowiec I,Moren L,et al. Metabolomic patterns in glioblastoma and changes during radiotherapy:a clinical microdialysis study [J]. J Proteome Res,2010,9(6):2909-2919.
[5] Sugimoto M,Sakagami H,Yokote Y,et al. Non-targeted metabolite profiling in activated macrophage secretion [J]. Metabolomics,2012,8(4):624-633.
[6] Kelly B,O’neill LA. Metabolic reprogramming in macr-ophages and dendritic cells in innate immunity [J]. Cell Res,2015,25(7):771-784.
[7] Sasikaran J,Ziemski M,Zadora PK,et al. Bacterial itaconate degradation promotes pathogenicity [J]. Nat Chem Biol,2014,10(5):371-377.
[8] Rittenhouse JW,Mcfadden BA. Inhibition of isocitrate lyase from Pseudomonas indigofera by itaconate [J]. Arch Biochem Biophys,1974,163(1):79-86.
[9] Wynn TA,Chawla A,Pollard JW. Macrophage biology in development,homeostasis and disease [J]. Nature,2013, 496(7446):445-455.
[10] Weiss JM,Davies LC,Karwan M,et al. Itaconic acid mediates crosstalk between macrophage metabolism and peritoneal tumors [J]. J Clin Invest,2018,128(9):3794-3805.
[11] Bambouskova M,Gorvel L,Lampropoulou V,et al. Electrophilic properties of itaconate and derivatives regulate the IkappaBzeta-ATF3 inflammatory axis [J]. Nature,2018,556(7702):501-504.
[12] Schuetz P,Mueller B. Procalcitonin:An Effective Screening Tool and Safe Therapeutic Decisionmaking Aid for Emergency Department Patients With Suspected Sepsis [J]. Ann Emerg Med,2015,66(3):318-319.
[13] Sakai A,Kusumoto A,Kiso Y,et al. Itaconate reduces visceral fat by inhibiting fructose 2,6-bisphosphate synthesis in rat liver [J]. Nutrition,2004,20(11/12):997-1002.
[14] Kuo PC,Weng WT,Scofield BA,et al. Dimethyl itaconate,an itaconate derivative,exhibits immunomodulatory effects on neuroinflammation in experimental autoimmune encephalomyelitis [J]. J Neuroinflammation,2020,17(1):138.
[15] Michelucci A,Cordes T,Ghelfi J,et al. Immune-responsive gene 1 protein links metabolism to immunity by catalyzing itaconic acid production [J]. Proc Natl Acad Sci USA,2013,110(19):7820-7825.
[16] Scott DL,Wolfe F,TWJ. Huizinga. Rheumatoid arthritis [J]. Nat Rev Dis Primers,2018,4(18002):659-672.
[17] Michopoulos F,Karagianni N,Whalley NM,et al. Targeted Metabolic Profiling of the Tg197 Mouse Model Reveals Itaconic Acid as a Marker of Rheumatoid Arthritis [J]. J Proteome Res,2016,15(12):4579-4590.
[18] Reece EA. The fetal and maternal consequences of gestational diabetes mellitus [J]. J Matern Fetal Neonatal Med,2010,23(3):199-203.
[19] Correa PJ,Vargas JF,Sen S,et al. Prediction of gestational diabetes early in pregnancy:targeting the long-term complications [J]. Gynecol Obstet Invest,2014,77(3):145-149.
[20] Gobl CS,Bozkurt L,Yarragudi R,et al. Is early postpartum HbA1c an appropriate risk predictor after pregnancy with gestational diabetes mellitus? [J]. Acta Diabetol,2014,51(5):715-722.
[21] de Seymour JV,Conlon CA,Sulek K,et al. Early pregnancy metabolite profiling discovers a potential biomarker for the subsequent development of gestational diabetes mellitus [J]. Acta Diabetol,2014,51(5):887-890.
[22] Lampropoulou V,Sergushichev A,Bambouskova M,et al. Itaconate Links Inhibition of Succinate Dehydrogenase with Macrophage Metabolic Remodeling and Regulation of Inflammation [J]. Cell Metab,2016,24(1):158-166.
[23] Luan HH,Medzhitov R. Food Fight:Role of Itaconate and Other Metabolites in Antimicrobial Defense [J]. Cell Metab,2016,24(3):379-387.
[24] Meiser J,Kraemer L,Jaeger C,et al. Itaconic acid indicates cellular but not systemic immune system activation [J]. Oncotarget,2018,9(63):32098-32107.
[25] Cordes T,Wallace M,Michelucci A,et al. Immunoresponsive Gene 1 and Itaconate Inhibit Succinate Dehydrogenase to Modulate Intracellular Succinate Levels [J]. J Biol Chem,2016,291(27):14274-14284.
[26] Shen H,Campanello GC,Flicker D,et al. The Human Knockout Gene CLYBL Connects Itaconate to Vitamin B12 [J]. Cell,2017,171(4):771-782.
[27] Naujoks J,Tabeling C,Dill BD,et al. IFNs Modify the Proteome of Legionella-Containing Vacuoles and Restrict Infection Via IRG1-Derived Itaconic Acid [J]. PLoS Pathog,2016,12(2):e1005408.
[28] Cho H,Proll SC,Szretter KJ,et al. Differential innate immune response programs in neuronal subtypes determine susceptibility to infection in the brain by positive-stranded RNA viruses [J]. Nat Med,2013,19(4):458-464.
[29] Macmicking JD. Interferon-inducible effector mechanisms in cell-autonomous immunity [J]. Nat Rev Immunol,2012,12(5):367-382.
[30] Daniels BP,Kofman SB,Smith JR,et al. The Nucleotide Sensor ZBP1 and Kinase RIPK3 Induce the Enzyme IRG1 to Promote an Antiviral Metabolic State in Neurons [J]. Immunity,2019,50(1):64-76.
[31] Zhang Q,Tang X,Liu Z,et al. Hesperetin Prevents Bone Resorption by Inhibiting RANKL-Induced Osteoclastogenesis and Jnk Mediated Irf-3/c-Jun Activation [J]. Front Pharmacol,2018,9:1028.
[32] Sun X,Zhang B,Pan X,et al. Octyl itaconate inhibits osteoclastogenesis by suppressing Hrd1 and activating Nrf2 signaling [J]. FASEB J,2019,33(11):12929-12940.
[33] Remuzzi G,Bertani T. Pathophysiology of progressive neph-ropathies [J]. N Engl J Med,1998,339(20):1448-1456.
[34] Meng XM,Nikolic-Paterson DJ,Lan HY. TGF-beta:the master regulator of fibrosis [J]. Nat Rev Nephrol,2016, 12(6):325-338.
[35] Tian F,Wang Z,He J,et al. 4-Octyl itaconate protects against renal fibrosis via inhibiting TGF-beta/Smad pathway,autophagy and reducing generation of reactive oxygen species [J]. Eur J Pharmacol,2020,873:172989.
[36] Romero I,Bast Jr RC. Minireview:human ovarian cancer:biology,current management,and paths to personalizing therapy [J]. Endocrinology,2012,153(4):1593-1602.
[37] Henderson IC,Frei TE,3rd. Adriamycin and the heart [J]. N Engl J Med,1979,300(6):310-312.
[38] Shan Q,Li X,Zheng M,et al. Protective effects of dimethyl itaconate in mice acute cardiotoxicity induced by doxorubicin [J]. Biochem Biophys Res Commun,2019,517(3):538-544.
[39] Ganta VC,Choi MH,Kutateladze A,et al. A MicroRNA93-Interferon Regulatory Factor-9-Immunoresponsive Gene-1-Itaconic Acid Pathway Modulates M2-Like Macrophage Polarization to Revascularize Ischemic Muscle [J]. Circulation,2017,135(24):2403-2425.
[40] Eltzschig HK,Eckle T. Ischemia and reperfusion--from mechanism to translation [J]. Nat Med,2011,17(11):1391-1401.
[41] Cordes T,Lucas A,Divakaruni AS,et al. Itaconate modulates tricarboxylic acid and redox metabolism to mitigate reperfusion injury [J]. Mol Metab,2020,32(1):122-135.
[1]
封继宏1 谭旺晓2 张硕1 金世元3 毕明达2 秦云普2 赵坤4. 射麻口服液治疗新型冠状病毒肺炎作用机制的网络药理学探讨 [J]. 中国医药导报, 2021, 18(8): 4-9,24.
[2]
卓丹1 王宇红1,2 于静波1,2 赵洪庆2 李姿蓉1 蔺晓源2,3 贺海霞3 姚欣艳3. 复方柴金解郁片治疗抑郁症的效果及对血清炎症因子和神经递质的影响 [J]. 中国医药导报, 2021, 18(8): 114-117,129.
[3]
谢秋芳 张意侗 梁贵廷 段俊红 魏萱 王娟 刘博 樊玉珠. 虫草补肾胶囊治疗气阴两虚型糖尿病肾病患者的效果 [J]. 中国医药导报, 2021, 18(8): 157-160.
[4]
张磊1 李维力2 王春3▲. 布地奈德混悬液联合异丙托溴铵在COPD患者中的应用效果及对肺功能的影响 [J]. 中国医药导报, 2021, 18(4): 90-93.
[5]
陈栋1 朱峰2 龚杰1 耿德春3 王德超4. 改良Stoppa与经髂腹股沟入路用于髋臼骨折的临床观察 [J]. 中国医药导报, 2021, 18(3): 84-87,92.
[6]
姜荣荣 顾嘉美. 甘草附子汤加减辅助西药治疗中风后偏瘫对患者炎症因子、Klotho蛋白的影响 [J]. 中国医药导报, 2021, 18(3): 156-159,180.
[7]
殷智宇 阮文晴 孙龙 魏盼 宋建钢. 去氢紫堇碱对慢性炎性痛小鼠痛行为学及脊髓炎症因子表达的影响 [J]. 中国医药导报, 2021, 18(2): 4-7,11.
[8]
徐新娟1 王士洲1 黄忻涛2▲ 闫青云2 王策1. 新型标志物血清外泌体miRNA在颅脑创伤诊断和监测预后的研究进展 [J]. 中国医药导报, 2021, 18(2): 35-38.
[9]
黄静文 魏燕燕▲ 刘艳. 老年抑郁症患者体重降低的影响因素分析 [J]. 中国医药导报, 2021, 18(2): 114-117.
[10]
努尔比亚木·麦麦提依明 吴龙 赵今. 牙髓炎的发病机制和分子靶标研究 [J]. 中国医药导报, 2021, 18(1): 22-26.
[11]
郑爱东1 严锡祥1 崔永华2 张振恩1 潘国翠1. 益生菌强化肠内营养支持对重度颅脑损伤患者肠黏膜屏障功能及炎症因子的影响 [J]. 中国医药导报, 2021, 18(1): 83-86,91.
[12]
王美华 王甲 韩丹 王羽. 小檗碱对氧糖剥夺/复氧诱导的大鼠体外血脑屏障损伤的保护作用 [J]. 中国医药导报, 2020, 17(9): 16-20.
[13]
蔡彬1 周敏红2 李春伟1▲. 氨基酸在炎症性肠病治疗中的研究进展 [J]. 中国医药导报, 2020, 17(9): 37-40.
[14]
韦婷艳1,2 杨杰3 曾宇婷4 黄绮亭4 刘钰君4. NLRP3炎症小体和氧化应激在新生儿缺氧缺血性脑病患者胎盘组织中的表达及其临床意义 [J]. 中国医药导报, 2020, 17(8): 17-20.
[15]
周艳丽1,2 许剑怡2 王宏娟2 刘蕊1,3 张景照1,3 赵欣1,3 唐旭东1,3. 虫草素的药理作用及应用前景 [J]. 中国医药导报, 2020, 17(8): 39-42.